Skip to main content
. 2016 Aug 19;19(4):417–425. doi: 10.1093/ntr/ntw200

Table 2.

Results From the JAG Test in EAs

Gene No. of SNPs No. of effective SNPsa COPDGene Pemp SAGE Pemp MESA Pemp CADD-GADD Pemp Combined Pemp FDR corrected P
CPD
CHRNA3 102 2 .0001 .128 .209 .434 .0001 .013
CHRNA5 29 1 .0001 .304 .348 .620 .0001 .013
CHRNB4 17 3b .0001 .639 .742 .212 .0001 .013
NCAM1 402 5c .006 .154 .721 .337 .004 .193
CHRNE 79 3 .004 .182 .924 .800 .005 .193
DNAJA3 111 2 .004 .527 .900 .472 .007 .258
IQGAP1 246 2 .010 .898 .268 .813 .022 .556
MAPRE1 148 5 .015 .829 .784 .196 .025 .601
UNC50 53 1 .043 .181 .514 .249 .029 .644
CHRNB1 63 3 .038 .216 .878 .531 .039 .729
EPHA4 212 5 .133 .073 .238 .105 .064 .782
NRXN1 2433 22d .022 .992 .516 .493 .064 .782
LRP4 106 3e .089 .178 .599 .441 .070 .782
CRELD2 127 1f .097 .009 .638 .991 .071 .782
CAMK2A 89 5 .178 .059 .034 .174 .075 .782
ITGA7 41 1 .075 .451 .725 .304 .078 .782
APC 231 2 .061 .245 .876 .920 .079 .782
FTND
CHRNA3 102 2 .003 .028 NA NA .00042 .042
CHRNA5 29 1 .012 .060 NA NA .003 .193
CHRNB4 17 2 .012 .080 NA NA .004 .193
CHRNA9 239 4 .009 .221 NA NA .008 .280
DNAJA3 111 2 .008 .338 NA NA .012 .381
CHRNE 79 3 .218 .004 NA NA .017 .482
EPHA4 212 5 .116 .112 NA NA .048 .782
CAMK2G 61 2 .008 .794 NA NA .056 .782
SVEP1 598 13 .263 .035 NA NA .064 .782
CAMK2A 89 5 .368 .013 NA NA .067 .782
ERBB2 64 1 .049 .458 NA NA .075 .782
RAPSN 65 2 .253 .056 NA NA .077 .782
CRELD2 127 1 .237 .073 NA NA .081 .782
LRP4 106 3g .106 .269 NA NA .084 .782

The P-value is shown for each study as well as the combined P-value for genes associated with CPD or FTND at P < .1.

aThe number of signals tested in the gene in each study (unless otherwise noted) as calculated by JAG.

bOnly two signals calculated in the COPDGene sample.

cSix signals calculated in the COPDGene sample.

dTwenty-three signals calculated in the CADD-GADD and MESA samples.

eTwo signals calculated in the SAGE sample.

fTwo signals calculated in the MESA sample.

gTwo signals calculated in SAGE.